Fortress Biotech, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FBIOP research report →
Price Chart
About the company
Fortress Biotech, Inc. operates as a biopharmaceutical firm dedicated to the development and commercialization of a diverse range of pharmaceutical and biotechnology products. The company currently offers a portfolio of dermatological treatments.
- CEO
- Lindsay A. Rosenwald
- IPO
- 2017
- Employees
- 78
- HQ
- Bay Harbor Islands, FL, US
Get TickerSpark's AI analysis on FBIOP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $56.02M
- P/E
- 0.65
- Fwd P/E
- 5.22
- PEG
- 0.00
- P/S
- 0.91
- P/B
- 0.40
- EV/EBITDA
- -0.35
- Div Yield
- 0.00%
- Gross Margin
- 63.17%
- Op Margin
- -42.47%
- Net Margin
- 143.05%
- ROE
- 74.69%
- ROIC
- -13.12%
Latest fiscal year · YoY change
- Revenue
- $63.26M+9.7%
- Gross Profit
- $42.34M+15.1%
- Op Income
- $-70,221,000
- Net Income
- $6.82M+114.8%
- EPS
- $-0.07+97.5%
- OCF Growth
- +18.0%
- FCF Growth
- +30.9%
- 52W High
- $21.43
- 52W Low
- $6.50
- 50D MA
- $16.30
- 200D MA
- $16.43
- Beta
- 1.21
- RSI (14)
- 28
- Avg Volume
- 13.04K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Journey Medical posted 8% revenue growth, a second straight quarter of positive EBITDA, and strong Emrosi momentum, while setting up for potentially better access and ASPs as 2027 formulary wins roll in.· November 12, 2026
- Total revenue rose 8% year over year to $19 million, with net product sales up 11% and Emrosi net revenue at $9 million.
- Gross margin improved to 69% from 67%, and the company reported positive EBITDA for the second consecutive quarter.
- Emrosi prescriptions reached about 40,000 in Q3, up from about 36,000 in Q2, while unique prescribers rose to over 5,000.
- Management said a large national plan covering over 25 million lives should go live in early 2027, with more formulary wins expected.
- A one-time $1.7 million vendor settlement weighed on SG&A, but management expects SG&A to stay flat to slightly lower as a percentage of revenue.
Total revenue was $19 million in Q3 2026 versus $15 million in Q3 2025, an 8% increase. Net product sales increased 11% year over year, and Emrosi generated $9 million in net revenue. Gross margin was 69% versus 67% a year ago. SG&A was $12.6 million versus $12.1 million in Q3 2025, including a one-time $1.7 million settlement expense with a former vendor. GAAP net loss narrowed to $1.3 million, or $0.05 per share, from $3.9 million, or $0.14 per share, last year; adjusted EBITDA and EBITDA were both positive. The company ended the quarter with $22.3 million in cash versus $24.1 million at December 31, 2025. For guidance, management did not give formal 2027 revenue or EBITDA guidance, but said it expects Emrosi ASP and revenue to trend higher as more reimbursed prescriptions and national formulary wins come through, with the large national plan expected to begin in Q1 2027 and additional wins possible thereafter.
Claude Maraoui described the quarter as another step forward, emphasizing top-line growth, improved profitability, and Emrosi’s expanding prescriber base. He highlighted that unique Emrosi prescribers exceeded 5,000, above the company’s internal goal for the year, and said refill strength and improved payer coverage support the brand’s momentum. His tone was upbeat but measured, repeatedly tying future growth to continued formulary access, more clinical awareness, and disciplined investment.
Joseph Benesch focused on the quarter’s financial improvements and the composition of costs. He noted revenue of $19 million, gross margin of 69%, GAAP net loss of $1.3 million, and positive adjusted EBITDA, while explaining that SG&A of $12.6 million included a nonrecurring $1.7 million payment tied to a former vendor dispute. He said the company ended with $22.3 million in cash and expects SG&A to remain consistent or decline slightly as a percentage of revenue even as it continues to invest in the Emrosi launch and added sales resources.
Analysts focused on Emrosi pricing, formulary coverage, and whether the October payer transition would affect Q4. Management said the October copay-bridging change created some short-term volatility, but that recovery is underway and December should be a strong month; they also said the next large national plan, covering over 25 million lives, should materially help ASP and revenue starting in Q1 2027. On spending, management said they added five sales reps and may add more in 2027, while keeping SG&A disciplined. When asked about 2027 guidance, the company said it is strongly considering providing formal guidance but wants to see how the new formulary wins and patient mix stabilize first.
The call showed sustained commercial traction for Emrosi, with prescriptions, prescribers, and refills all moving in the right direction. Management also pointed to better payer access, a large upcoming national formulary win, and a growing base of reimbursed business as catalysts for higher ASPs and stronger profitability in 2027.
Management acknowledged short-term volatility from changes to the copay-bridging program and said first-quarter deductible resets may delay some of the benefit from the new national formulary win. They also stopped short of giving formal 2027 guidance, suggesting visibility is still incomplete even though the outlook is improving. The company is still spending on sales force and market access, and the Q3 results included a one-time $1.7 million vendor settlement that reduced earnings.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 100.0%
- Shares Outstanding
- 3.43M
- Float Shares
- 3.43M
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 19, 26 | ROSENWALD LINDSAY A MD | buy | 17,456 |
| Nov 18, 26 | ROSENWALD LINDSAY A MD | buy | 54,776 |
| Nov 17, 26 | ROSENWALD LINDSAY A MD | buy | 64,491 |
| Nov 19, 26 | Jin David | buy | 7,605 |
| Nov 18, 26 | Jin David | buy | 25,000 |
| Nov 17, 26 | Jin David | buy | 15,000 |
| Oct 1, 26 | Jin David | other | 1,190 |
| Jun 22, 26 | Jin David | other | 400,000 |
| Apr 1, 26 | Jin David | other | 2,967 |
| Mar 18, 26 | ROSENWALD LINDSAY A MD | other | 475,424 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our FBIOP coverage
Recent articles, reports, and earnings notes.
No research on FBIOP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate FBIOP report →Fortress Biotech Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
globenewswire.com · Nov 13
Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference
globenewswire.com · Sep 8
Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
globenewswire.com · Aug 13
Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends?
seekingalpha.com · May 29
Fortress Biotech to Participate in A.G.P.'s Annual Virtual Healthcare Conference
globenewswire.com · May 18
Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
globenewswire.com · May 14
Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
globenewswire.com · May 4
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights
globenewswire.com · Mar 31
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.